Werewolf Therapeutics, Merck collaborate on WTX-124 INDUKINE Program

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

Werewolf Therapeutics Inc. has entered into a clinical trial collaboration and supply agreement with Merck to evaluate WTX-124, a systemically-delivered, conditionally activated Interleukin-2 (IL-2) INDUKINE product candidate, in combination with Keytruda (pembrolizumab), Merck’s anti-PD-1 therapy. 

To access this subscriber-only content please log in or renew your subscription.

Looking for IP Login? Our IP Login system is now automatic. If your institution has a site license, please log in from on site or via your VPN to access this content.

Login Subscribe
Table of Contents

YOU MAY BE INTERESTED IN

Login